Early Research


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1476. Categories: , .

Product Description

The way new medicines are discovered is on the cusp of revolutionary change. Advances in the understanding of the body at the molecular level and of the diseases that affect people are likely to have a tremendous impact on the development of new medicines.
Experts say bioinformatics and predictive technologies will have the greatest impact, enabling researchers to test and simulate the effects of drugs and biologics on specific targets before the first dose in humans. In fact, analysts from PricewaterhouseCoopers (PWC) predict that by 2020, virtual cells, organs, and animals will be widely used in pharmaceutical research.
“There continue to be significant investments in the field of regenerative medicine, from Pfizer to the U.S. military,” says Steven Nichtberger, M.D., president and CEO of Tengion. “Within the next five years, it is possible that patients could receive bioengineered organs built from their own cells that harness the body’s ability to regenerate instead of repair.”
According to experts at PWC, over the next decade, researchers must gain a much better understanding of the biology of disease. Pharmaceutical companies will need to build a portfolio of products that demonstrate value within the healthcare continuum, use new technology to better manage and share…

Vital Features For Research
Global Drug-Discovery Outsourcing Market 2005-2013
Outsourcing in Drug Discovery

Joseph Amprey, M.D., Ph.D. Senior Managing Director, MedImmune Ventures, Gaithersburg, Md.; MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. For more information, visit
Lee Babiss, Ph.D. Global Head of Pharma Research, Roche, Basel, Switzerland; Roche is one of the world’s leading research-oriented healthcare groups in the fields of pharmaceuticals and diagnostics. For more information, visit
Douglas D. Burkett, Ph.D. President, Champions Biotechnology Inc., Arlington, Va.; Champions Biotechnology is engaged in the development of advanced preclinical platforms and predictive tumor-specific data to enhance and accelerate the value of oncology drugs. For more information, visit
Diana Faulds. Director, Global Content Creation, Wolters Kluwer Health, Conshohocken, Pa.; Wolters Kluwer Health is a provider of information for professionals and students in medicine, nursing, allied health, pharmacy, and the pharmaceutical industry. For more information, visit
Bille-Jo (BJ) Kerns. VP, Strategic Marketing and Business Development, High Throughput Genomics (HTG), Tucson, Ariz.; HTG is a provider of the quantitative Nuclease Protection Assay system and service partner for the life-sciences industry. For more information, visit
Peter Lanciano. CEO, Neotropix Inc., Malvern, Pa.; Neotropix develops and commercializes systemically deliverable oncolytic viruses for the treatment of solid tumors. For more information, visit
Martin Mackay, Ph.D. President, Pfizer Global Research and Development, Groton, Conn.; Pfizer is dedicated to better health and greater access to healthcare for people and their valued animals. For more information, visit
Steven Nichtberger, M.D. President and CEO, Tengion, East Norriton, Pa.; Tengion is a clinical-stage biotechnology company
developing neo-organs and tissues derived from a patient’s own cells. For more information, visit
John A. “Jack” Secrist III, Ph.D. President and CEO, Southern Research Institute, Birmingham, Ala.; Southern Research Institute is a diversified network of collaborative centers for scientific discovery and technology development. For more information, visit